Stock Events

Stock Events

Monopar Therapeutics 

€48
35
+€1.45+3.11% Wednesday 07:16

Statistics

Day High
48
Day Low
48
52W High
80.5
52W Low
25.6
Volume
-
Avg. Volume
-
Mkt Cap
320.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.93
-0.72
-0.51
-0.3
Expected EPS
-0.70651806812
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-29.91MNet Income

Analyst Ratings

83.85Average Price Target
The highest estimate is 93.33.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1IY0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for life-threatening diseases, overlapping with Monopar's focus on severe and life-threatening diseases.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotech firm focusing on novel therapies, including for cancer and other serious illnesses, directly competing with Monopar's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb operates in the oncology space, developing cancer treatments that could compete with Monopar's cancer-focused pipeline.
Merck
MRK
Mkt Cap300.2B
Merck is known for its strong oncology portfolio, including therapies for various cancers, which competes with Monopar's cancer treatment developments.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a broad range of therapeutic products, including in oncology, which competes with Monopar's focus areas.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie has a significant presence in oncology and other serious health conditions, competing with Monopar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals focuses on developing drugs for serious diseases, including cancer, making it a competitor to Monopar.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, competing with Monopar's focus.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca has a significant oncology portfolio, directly competing with Monopar's cancer therapy developments.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for various diseases, including cancer, competing with Monopar's therapeutic focus.

About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Show more...
CEO
Dr. Christopher M. Starr Ph.D.
Employees
22
Country
United States
ISIN
US61023L2079
WKN
000A40JML

Listings

STU
DE
1IY0.STU
MU
DE
1IY0.MU
F
DE
1IY0.F
XNAS
US
MNPR

0 Comments

Share your thoughts

FAQ

What is Monopar Therapeutics stock price today?▼
The current price of 1IY0.F is €48 EUR — it has increased by +3.11% in the past 24 hours. Watch Monopar Therapeutics stock price performance more closely on the chart.
What is Monopar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Monopar Therapeutics stocks are traded under the ticker 1IY0.F.
Is Monopar Therapeutics stock price growing?▼
1IY0.F stock has fallen by -0.72% compared to the previous week, the month change is a -4.95% fall, over the last year Monopar Therapeutics has showed a +70.21% increase.
What is Monopar Therapeutics market cap?▼
Today Monopar Therapeutics has the market capitalization of 320.78M
When is the next Monopar Therapeutics earnings date?▼
Monopar Therapeutics is going to release the next earnings report on May 07, 2026.
What were Monopar Therapeutics earnings last quarter?▼
1IY0.F earnings for the last quarter are -0.41 EUR per share, whereas the estimation was -0.33 EUR resulting in a -24.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Monopar Therapeutics revenue for the last year?▼
Monopar Therapeutics revenue for the last year amounts to 0 EUR.
What is Monopar Therapeutics net income for the last year?▼
1IY0.F net income for the last year is -29.91M EUR.
How many employees does Monopar Therapeutics have?▼
As of April 19, 2026, the company has 22 employees.
In which sector is Monopar Therapeutics located?▼
Monopar Therapeutics operates in the Other sector.
When did Monopar Therapeutics complete a stock split?▼
The last stock split for Monopar Therapeutics was on August 13, 2024 with a ratio of 1:5.
Where is Monopar Therapeutics headquartered?▼
Monopar Therapeutics is headquartered in Wilmette, United States.